Gadopiclenol

Gadopiclenol
Clinical data
Trade namesElucirem, others
AHFS/Drugs.comMicromedex Detailed Consumer Information
License data
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
MetabolismNone
ExcretionKidneys
Identifiers
  • 2-[3,9-bis[1-carboxylato-4-(2,3-dihydroxypropylamino)-4-oxobutyl]-3,6,9,15-tetrazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-6-yl]-5-(2,3-dihydroxypropylamino)-5-oxopentanoate;gadolinium(3+)
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC35H54GdN7O15
Molar mass970.10 g·mol−1
3D model (JSmol)
  • [Gd+3].OCC(O)CNC(=O)CCC(N1CCN(Cc2cccc(CN(CC1)C(CCC(=O)NCC(O)CO)C(=O)[O-])n2)C(CCC(=O)NCC(O)CO)C(=O)[O-])C(=O)[O-]
  • InChI=1S/C35H57N7O15.Gd/c43-19-24(46)14-36-30(49)7-4-27(33(52)53)40-10-12-41(28(34(54)55)5-8-31(50)37-15-25(47)20-44)17-22-2-1-3-23(39-22)18-42(13-11-40)29(35(56)57)6-9-32(51)38-16-26(48)21-45;/h1-3,24-29,43-48H,4-21H2,(H,36,49)(H,37,50)(H,38,51)(H,52,53)(H,54,55)(H,56,57);/q;+3/p-3
  • Key:GNRQMLROZPOLDG-UHFFFAOYSA-K

Gadopiclenol, sold under the brand name Elucirem among others, is a contrast agent used with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in the central nervous system and in the body. Gadopiclenol is a paramagnetic macrocyclic non-ionic complex of gadolinium.

Gadopiclenol was approved for medical use in the United States in September 2022, and in the European Union in December 2023.

Medical uses

Gadopiclenol is indicated for use with magnetic resonance imaging to detect and visualize lesions with abnormal vascularity in the central nervous system (brain, spine, and associated tissues); or the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system).

Pharmacology

Gadopiclenol has a higher relaxivity compared with standard gadolinium-based contrast agents (GBCAs). The higher relaxivity allows for a lower dose of gadopiclenol, reducing the total amount of gadolinium administered to the patient while preserving imaging quality. Gadopiclenol was approved by the FDA with a recommended dose of 0.05 mmol/kg for adults and pediatric patients aged 2 years and older. This is half the dose of standard macrocyclic GBCAs, which have a recommended dose of 0.1 mmol/kg.

History

Gadopiclenol was develped by Guerbet and Bracco Imaging.

Society and culture

Gadopiclenol was approved for medical use in the United States in September 2022.

In October 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Elucirem, intended for contrast-enhanced magnetic resonance imaging (MRI) to improve detection and, visualization of pathologies when diagnostic information is essential and not available with unenhanced MRI. The applicant for this medicinal product is Guerbet. In October and December 2023, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal products Elucirem and Vueway, intended for contrast-enhanced magnetic resonance imaging (MRI) to improve detection and, visualization of pathologies when diagnostic information is essential and not available with unenhanced MRI. Gadopiclenol was approved for medical use in the European Union in December 2023.

Brand names

Gadopiclenol is the international nonproprietary name.

Gadopiclenol is sold under the brand names Vueway and Elucirem.